

Russian Federation

Population 2017

144 million

Estimates of TB burden*, 2017	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	10 (9.4–12)	7.3 (6.6–8)
Mortality (HIV+TB only)	1.7 (0.85–2.8)	1.2 (0.59–1.9)
Incidence (includes HIV+TB)	86 (56–123)	60 (39–85)
Incidence (HIV+TB only)	18 (12–26)	13 (8.3–18)
Incidence (MDR/RR-TB)**	42 (27–60)	29 (19–42)

Estimated TB incidence by age and sex (thousands)*, 2017

	0-14 years	> 14 years	Total
Females	1.4 (0.64–2.1)	25 (12–38)	26 (13–40)
Males	1.2 (0.57–1.8)	59 (28–90)	60 (29–91)
Total	2.6 (1.5–3.6)	84 (50–117)	86 (56–123)

TB case notifications, 2017

Total cases notified	114 187
Total new and relapse	84 510
- % tested with rapid diagnostics at time of diagnosis	78%
- % with known HIV status	96%
- % pulmonary	92%
- % bacteriologically confirmed among pulmonary	52%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2017	98% (69–150)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2017	0.15 (0.09–0.21)

TB/HIV care in new and relapse TB patients, 2017

	Number	(%)
Patients with known HIV-status who are HIV-positive	15 695	19%
- on antiretroviral therapy	9 748	62%

Drug-resistant TB care, 2017	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			49 000 (49 000–50 000)
Estimated % of TB cases with MDR/RR-TB	32% (31–33)	67% (66–67)	
% notified tested for rifampicin resistance	42%	58%	55 344
MDR/RR-TB cases tested for resistance to second-line drugs			23 098
Laboratory-confirmed cases		MDR/RR-TB: 26 602, XDR-TB: 3 661	
Patients started on treatment ****		MDR/RR-TB: 26 457, XDR-TB: 2 770	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2016	72%	73 137
Previously treated cases, excluding relapse, registered in 2016	49%	9 245
HIV-positive TB cases registered in 2016	53%	1 328
MDR/RR-TB cases started on second-line treatment in 2015	54%	22 607
XDR-TB cases started on second-line treatment in 2015	33%	2 882

TB preventive treatment, 2017

% of HIV-positive people (newly enrolled in care) on preventive treatment	97%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	> 100%

TB financing, 2018

National TB budget (US\$ millions)	1 435
Funding source: 100% domestic, 0% international, 0% unfunded	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2017




■ Females ■ Males □ Incidence

Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



■ Unfunded
■ Funded internationally
■ Funded domestically